You are currently browsing the archives for 14 September 2015.
Displaying 1 entry.

Richard Pazdur.

Richard Pazdur, director of the Office of Oncology Drug Products in the FDA stated:’Only patients with this cancer have few effective treatment options Afinitor has the ability to show the growth and spread of neuroendocrine tumors slows. Late stage ‘The FDA’s Oncologic Drugs Advisory Committee unanimously last month to the drug’s approval for pNET, the slow-growing and rare types of tumors are to be recommended, it is estimated that fewer than 1,000 new cases in the U.S. Every year. According to the FDA, but the treatment is hard to come by.

Angela Odoms-Young, assistant professor of kinesiology and nutrition, is co-principal investigator of the study, Carol Braunschweig, associate professor of kinesiology and nutrition, and Melinda Stolley, associate Professor of Medicine, Co – investigators are.